Indication for anticoagulation therapy
Risk stratum for thrombotic events
Mechanical heart valves
Atrial fibrillation
Venous thromboembolism
High risk
>10% annual risk for thromboembolism
Any mitral valve prosthesis
Any caged-ball or tilting disc aortic valve prosthesis
Recent (within 6 months) stroke or TIA
CHADS2 score of 5 of 6
Recent (within 3 months) stroke or TIA
Recent (within 3 months) VTE
Severe thrombophilia
Moderate risk
5–10% annual risk for thromboembolism
Bileaflet aortic valve prosthesis and ≥1 of the following risk factors: atrial fibrillation, prior stroke or TIA, hypertension, diabetes, CHF, age > 75 years
Rheumatic valvular heart disease
CHADS2 score of 3 or 4
VTE within the past 3–12 months
Recurrent VTE
Active cancer (treated within 6 months or palliative)
Nonsevere thrombophilia
Low risk
<5% annual risk for thromboembolism
Bileaflet aortic valve prosthesis without atrial fibrillation and no other risk factors for stroke
CHADS2 score of 0–2
VTE > 12 months previous and no other risk factors
33.6 Bleeding Risk Assessment
The assessment of bleeding risk requires assessment of patient- and procedure-specific characteristics. The extensive venous plexus of the epidural space is vulnerable to trauma from needle puncture, advancement of spinal cord stimulator leads, or epidural and intrathecal catheters. The fragility and caliber of these vessels increase with age and various physiologic or pathologic states. The anatomic narrowing of the spinal canal from a myriad of conditions may lower the threshold for neurologic compression and injury with spinal bleeding. Table 33.2, adapted from the ASRA 2015 guidelines for pain procedures, provides a risk assessment based on type of pain procedure.
High-risk procedures | Intermediate-risk proceduresa | Low-risk proceduresa |
---|---|---|
Spinal cord stimulation trial and implant Intrathecal catheter and pump implant Vertebral augmentation Epiduroscopy and epidural decompression | Interlaminar ESIs (C, T, L, S) Transforaminal ESIs (C,T, L, S) Facet MBNB and RFA (C, T, L) Paravertebral block (C, T, L) Intradiscal procedures (C, T, L) Sympathetic blocks (stellate, thoracic, splanchnic, celiac, lumbar, hypogastric) Peripheral nerve stimulation trial and implant Pocket revision and IPG/ITP replacement | Peripheral nerve blocks Peripheral joints and musculoskeletal injections Trigger point injections including piriformis injections Sacroiliac joint injections and sacral lateral branch blocks |
33.7 Discontinuing Anticoagulation or Antiplatelet Treatment
Concurrent use of coagulation-altering medications may increase the risk of bleeding without altering coagulation studies. Catheters are placed and removed at the nadir of anticoagulant activity. Additional anticoagulants should not be given immediately after catheter removal. Before initiating neuraxial anesthesia , the patient’s medication list should identify the presence of anticoagulant or antiplatelet therapy. Common anticoagulants encountered in the surgical setting include antiplatelet medications, oral anticoagulants, unfractionated heparin, low molecular weight heparin, serotonin reuptake inhibitors, and herbal preparations.